eNews
Home page > Comments


Comments

FDA to review Medivation, Astellas' prostate cancer drug in November

04.08.2012. | (Reuters) - Medivation Inc and Japanese partner Astellas Pharma Inc said the U.S. health regulator has set an action date of November 22 to review the companies' marketing application for their experimental prostate cancer drug....


Оставите Ваш коментр
*Име:

Е-пошта:


*Ваш коментар:
:) :D ;) B-) :P :-o :( x-(

*Сигурносни број: